shutterstock_452099194_brianpirwin

brianpirwin / Shutterstock.com

22 February 2019Americas

Indivior to launch generic after SCOTUS refuses petition

Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

12 July 2019 Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

Fed Circuit refusal paves way for Suboxone generics

5 February 2019 Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.

Indivior loses battle over Suboxone generic

22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.

More on this story

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

12 July 2019 Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

Fed Circuit refusal paves way for Suboxone generics

5 February 2019 Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.

Indivior loses battle over Suboxone generic

22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.

More on this story

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

12 July 2019 Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

Fed Circuit refusal paves way for Suboxone generics

5 February 2019 Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.

Indivior loses battle over Suboxone generic

22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?